Using radiofrequency ablation to treat indeterminate thyroid nodules
Radiofrequency Ablation for Indeterminate Bethesda III Thyroid Nodules
This study is testing whether using radiofrequency ablation can safely treat certain thyroid nodules without the need for surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Columbia University Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT05189808 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the efficacy and safety of radiofrequency ablation (RFA) for treating indeterminate Bethesda III thyroid nodules. It involves a chart review where patient data is collected before and after the RFA procedure, which uses image guidance to deliver high-frequency electrical currents to the nodules, generating heat to treat them. The study aims to provide insights into the outcomes of RFA, potentially reducing unnecessary surgeries for patients with benign nodules.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with indeterminate Bethesda III thyroid nodules that have been molecularly profiled as benign.
Not a fit: Patients with cardiac arrhythmias or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could reduce the need for surgical interventions in patients with indeterminate thyroid nodules, minimizing risks and complications.
How similar studies have performed: Other studies have shown promising results with radiofrequency ablation for thyroid nodules, indicating that this approach is gaining traction in clinical practice.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Indeterminate Bethesda III nodules that have been molecularly profiled benign with either Afirma Genomic Sequencing Classifier (GSC) or ThyroSeq v3 tests Exclusion Criteria: * cardiac arrthymias * pregnancy
Where this trial is running
New York, New York
- Columbia University — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Jennifer H Kuo, MD MS — Columbia University
- Study coordinator: Jennifer H Kuo, MD MS
- Email: jhk2029@cumc.columbia.edu
- Phone: 212-305-6969
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.